PlainPharmaWatch

CMS Open Payments · Program Year 2024

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation reported $1,485,745.25 across General Payments, Research, and Ownership to 3,663 physicians and teaching hospitals across 4,101 transactions.

See the rankings → How this is sourced
$1.5M Above-median payer
All-tracks total
4,101 Top quartile volume
Transactions
3,663 Top quartile reach
Recipients
−$9.4K
General Payments vs PY2023

Adaptive Biotechnologies Corporation reported $1,485,745.25 across all CMS Open Payments tracks (General + Research + Ownership) to 3,663 physicians and teaching hospitals in Program Year 2024 - ranking #529 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $462,295.25, averaging $405.61 per recipient.

How Adaptive Biotechnologies Corporation's $1.5M all-tracks total breaks down

Adaptive Biotechnologies Corporation's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

38/100

Total payments

F

24/100

Transaction volume

F

40/100

Physician reach

F

38/100

Payment type diversity

D

50/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer adaptive-biotechnologies-corporation Adaptive Biotechnologies Corporation

$1.5M · #529/1,925 · 0.0% industry · PY2024

  • TOT $1.5M
  • RANK #529
  • SHARE 0.0%
  • TXN 4,101
  • RCP 3,663
  • CAT 4
  • GEN $462.3K
  • ΔGEN −$9.4K
  • TOP1 19.5%
  • PY 2024

Volume peers

Nearest volume peer: Servier Pharmaceuticals LLC ($1.5M)

CardioFocus, Inc.$1.5MCook Research Incorporated$1.5MAdaptive Biotechnologies Cor…$1.5MServier Pharmaceuticals LLC$1.5MFUJIFILM Healthcare Americas…$1.5M
All-tracks payment totals near Adaptive Biotechnologies Corporation (CMS Open Payments PY2024)

Adaptive Biotechnologies Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Adaptive Biotechnologies Corporation's CMS-reported General Payments decreased by $9.4K (−2.0%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: ADAPTIVE BIOTECHNOLOGIES CORPORATIONPY2023: ADAPTIVE BIOTECHNOLOGIES CORPORATIONPY2024: Adaptive Biotechnologies Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$471.7KPY2024$462.3K
PY2023
$471,697.88
PY2024
$462,295.25

What the Data Shows for Adaptive Biotechnologies Corporation

The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Adaptive Biotechnologies Corporation, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.

Of the 4 general-payment categories charted below, "Consulting Fee" is the largest at $287.3K across 92 transactions, 62.1% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Adaptive Biotechnologies Corporation made 4 types of general payments. "Consulting Fee" is the largest category at $287.3K, 62.1% of General Payments.

Adaptive Biotechnologies Corporation reports 4 general-payment categories - the top three are Consulting Fee (62.1%), Food and Beverage (25.1%), and Space Rental or Facility Fees (6.4%). The remaining 1 category make up 6.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Adaptive Biotechnologies Corporation divides its payments

General-payment categories, ordered by reported total

1. Consulting Fee$287.3K2. Food and Beverage$116.2K3. Space Rental or Facility …$29.7K4. Travel and Lodging$29.2K
Payment Type Amount Transactions
Consulting Fee $287.3K 92
Food and Beverage $116.2K 3,468
Space Rental or Facility Fees $29.7K 11
Travel and Lodging $29.2K 92

Recipient Concentration in General Payments

The five largest recipient relationships account for $169,786.39 (36.7%) of $462,295.25 in this company's General Payments records across 2,335 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Adaptive Biotechnologies Corporation

The five named recipients with the highest reported General Payments from this company

Gaurav Singal$90.0KNicholas Short$26.1KRushang Patel$20.8KStephan Grupp$19.0KAnthony Mato$13.9K
  1. 1

    Gaurav Singal

    $90,048.00 across 12 reported transactions

  2. 2

    Nicholas Short

    $26,077.60 across 17 reported transactions

  3. 3

    Rushang Patel

    $20,767.52 across 7 reported transactions

  4. 4

    Stephan Grupp

    $19,009.52 across 6 reported transactions

  5. 5

    Anthony Mato

    $13,883.75 across 5 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Adaptive Biotechnologies Corporation ranks #529 of 1,925 by total payments (top 27% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,294 of 1,838 by HHI (bottom 30% least concentrated), a wider distribution than most similarly sized payers.

01.83.75.57.3485.1490.1495499.9504.9Total payments ($M)Concentration (HHI, 0-10,000)
Adaptive Biotechnologies Corporation (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Adaptive Biotechnologies Corporation's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Adaptive Biotechnologies Corporation.

Nxstage Medical, Inc.

HHI 496

Alnylam Pharmaceuticals Inc.

HHI 498

Merge Healthcare Incorporated

HHI 499

Iovance Biotherapeutics, Inc.

HHI 489

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Adaptive Biotechnologies Corporation.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Adaptive Biotechnologies Corporation ranks #529 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Adaptive Biotechnologies Corporation's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.